Skip to main content

Table 1 Overall M. genitalium prevalence and number of M. genitalium positive specimens after confirmation testing (2007–2014)

From: Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014

Year Study* Males Females
N M. genitalium prevalence M. genitalium used in this study after confirmation N M. genitalium prevalence M. genitalium used in this study after confirmation
n %# n %§ n %# n %§
2007 NMS 205 31 15.1 2 6.5 200 23 11.5 1 4.3
2007 PLWHA 550 39 7.1 16 41.0 558 29 5.2 8 27.6
2008 NMS 433 37 8.5 14 37.8 312 32 10.3 13 40.6
2009 NMS 499 45 9.0 13 28.9 492 40 8.1 7 17.5
2010 NMS 427 38 8.9 27 71.1 393 51 13.0 36 70.6
2011 NMS 261 21 8.0 16 76.2 220 19 6.4 15 78.9
2012 NMS 198 16 8.1 15 93.8 207 20 9.7 16 80.0
2013 NMS 280 23 8.2 13 56.5 199 27 13.6 25 92.6
2014 NMS 206 11 5.3 10 90.9 199 24 12.1 19 79.2
Total Total 3059 261 8.5 126 48.3 2780 265 9.5 140 52.8
  1. * NMS National Microbiological Surveillance study (symptomatic patients), PLWHA People living with HIV/AIDS study (asymptomatic patients)
  2. # Percentage of genital discharge specimens that initially tested positive for M. genitalium
  3. § Percentage of stored DNA specimens that tested M. genitalium positive after confirmatory testing in this study